Ridge Bio has secured $47.0 million in new investment capital. The funding round will support the company's ongoing efforts in developing advanced precision therapeutics. Ridge Biotechnologies is pioneering AI-based enzyme and targeted drug design, aiming to power the next wave of innovative treatments for patients.
The company, led by a collection of established biotech entrepreneurs and faculty from top institutions, utilizes proprietary machine learning models. These models are informed by high-throughput cell-free experimentation, enabling a wide range of applications. Ridge Bio's technology is applied across various therapeutic areas, including antibody-drug conjugates (ADCs), conditionally active prodrugs, in vivo CART therapies, targeted nucleic acid delivery, radiotherapies, and enzyme-based therapeutics.
Ridge Bio's current product lines include NativeLink enzymes, which facilitate precision bioconjugation for constructing ADCs and Antibody-oligonucleotide conjugates. They also offer ProTrigger linkers, designed to provide tissue and disease-specific activation and release of diverse payloads and prodrugs. Additionally, the company is developing new classes of enzyme-based Catalytic Medicines.
This capital infusion is expected to accelerate Ridge Bio's strategic growth initiatives. The company plans to deploy the funds to expand its proprietary platform, advance its research and development pipeline, and scale its operations. This investment underscores confidence in Ridge Bio's innovative approach to drug discovery and development.
The company remains focused on its mission to enable partners in building better drugs for patients. This funding positions Ridge Bio to further its work in creating novel therapeutic solutions and expanding its impact within the biotechnology sector.
